Anti-Hu CD340 PE

*Bühring HJ, Sures I, Jallal B, Weiss FU, Busch FW, Ludwig WD, Handgretinger R, Waller HD, Ullrich A: The receptor tyrosine kinase p185HER2 is expressed on a subset of B-lymphoid blasts from patients with acute lymphoblastic leukemia and chronic myelogenous leukemia. Blood. 1995 Sep 1;86 (5) :1916-23., URL: https://pubmed.ncbi.nlm.nih.gov/7544646/, *Bühring HJ, Battula VL, Treml S, Schewe B, Kanz L, Vogel W: Novel markers for the prospective isolation of human MSC. Ann N Y Acad Sci. 2007 Jun;1106:262-71. , URL: https://www.ncbi.nlm.nih.gov/pubmed/17395729, *Tran T, Diniz MO, Dransart E, Gey A, Merillon N, Lone YC, Godefroy S, Sibley C, Ferreira LC, Medioni J, Oudard S, Johannes L, Tartour E: A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice. Clin Cancer Res. 2016 Aug 15;22 (16) :4133-44. , URL: https://www.ncbi.nlm.nih.gov/pubmed/27006496, *Bailey TA, Luan H, Tom E, Bielecki TA, Mohapatra B, Ahmad G, George M, Kelly DL, Natarajan A, Raja SM, Band V, Band H: A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells. J Biol Chem. 2014 Oct 31;289 (44) :30443-58., URL: https://pubmed.ncbi.nlm.nih.gov/25225290/

*Arora P, Cuevas BD, Russo A, Johnson GL, Trejo J: Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion. Oncogene. 2008 Mar 31, URL: https://www.ncbi.nlm.nih.gov/pubmed/18372913?ordin, *Northey JJ, Chmielecki J, Ngan E, Russo C, Annis MG, Muller WJ, Siegel PM: Northey JJ, Chmielecki J, Ngan E, Russo C, Annis MG, Muller WJ, Siegel PM: Signaling through ShcA is required for TGF-{beta} and Neu/ErbB-2 induced breast cancer cell motility and invasion. Mol Cell Biol. 2008 Mar 10, URL: https://www.ncbi.nlm.nih.gov/pubmed/18332126?ordin, *Yuan W, Wang W, Cui B, Su T, Ge Y, Jiang L, Zhou W, Ning G: Overexpression of ERBB-2 was more frequently detected in malignant than benign pheochromocytomas by multiplex ligation-dependent probe amplification and immunohistochemistry. Endocr Relat Cancer. 2008 Mar;15 (1) :343-50., URL: https://www.ncbi.nlm.nih.gov/pubmed/18310300?ordin, *Hicks DG, Kulkarni S: HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol. 2008 Feb;129 (2) :263-73., URL: https://www.ncbi.nlm.nih.gov/pubmed/18208807?ordin, *Dowsett M, Hanna WM, Kockx M, Penault-Llorca F, Rüschoff J, Gutjahr T, Habben K, van de Vijver MJ: Standardization of HER2 testing: results of an international proficiency-testing ring study. Mod Pathol. 2007 May;20 (5) :584-91., URL: https://www.ncbi.nlm.nih.gov/pubmed/17396141?ordin, *Koeppen HK, Wright BD, Burt AD, Quirke P, McNicol AM, Dybdal NO, Sliwkowski MX, Hillan KJ: Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology. 2001 Feb;38 (2) :96-104., URL: https://www.ncbi.nlm.nih.gov/pubmed/11207822?dopt=

The mouse monoclonal antibody 24D2 recognizes an extracellular epitope of human CD340 (HER-2), a type I transmembrane protein expressed by mesenchymal stem cells, B-lymphoblastic leukemia cells, subsets of C-ALL blasts, and and various types of carcinomas.